New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib

Janus kinases (JAK) are a family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) that transduce cytokine-mediated signals through the JAK–STAT metabolic pathway. These kinases act by regulating the transcription of specific genes capable of inducing biological responses in several immune cell subse...

Full description

Bibliographic Details
Main Authors: Annalisa Marcuzzi, Erika Rimondi, Elisabetta Melloni, Arianna Gonelli, Antonio Giacomo Grasso, Egidio Barbi, Natalia Maximova
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceuticals
Subjects:
Janus kinase
GVHD
ruxolitinib
pediatrics
cytokines
inflammation
Online Access:https://www.mdpi.com/1424-8247/15/3/374

Internet

https://www.mdpi.com/1424-8247/15/3/374

Similar Items